Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 3 extension study of inhaled liposomal cyclosporine A for bronchiolitis obliterans syndrome after lung transplantation
MOH_2020-03-31_008825Phase 3Not yet recruiting
- Sponsor
- Breath Therapeutics
- Start
- Feb 2020
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label trial of cyclosporine in Bronchiolitis Obliterans Syndrome (BOS) (2 arms), sponsored by Breath Therapeutics. Planned start Feb 2020; status: not yet recruiting.
02
Drugs
cyclosporine
03
Conditions
Bronchiolitis Obliterans Syndrome (BOS)
Beyond the preview
Go deeper on MOH_2020-03-31_008825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-03-31_008825.